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The molecular mechanisms of glycopeptide resistance in two Gram-positive clinical 
isolates, Bacillus lentus RSA1208 and Paenibacillus thiaminolyticus RSA1221 were 
investigated. The glycopeptide resistance genotypes were determined by PCR. If van genes 
were detected, recombinant DNA techniques and sequencing were used to determine the 
gene sequence. The location of the resistance determinant was investigated using Southern 
hybridization techniques. To determine the 5’ and 3’ ends flanking the resistance operon, 
sub-genomic libraries were constructed. Transmission electron microscopy was used to 
assess possible structural changes of the B. lentus RSA1208 cell wall.  
 
B. lentus RSA1208 exhibits inducible, high-level resistance to both glycopeptides, but does 
not possess any known van resistance genes. Electron micrographs showed a visible 
increase in cell wall thickness in B. lentus RSA1208 grown in vancomycin compared to the 
isolate grown in vancomycin-free media. However, it remains to be confirmed as to 
whether this resistance is solely responsible for the high-level resistance phenotype.  
 
P. thiaminolyticus RSA1221 exhibits constitutive, high-level resistance to vancomycin 
only. It was found to possess a chromosomally-borne, vanA gene cassette. The vanA gene 
showed the highest amino acid identity to the vanA-like D-ala: D-lac gene found in P. 
thiaminolyticus PT-2B1 and Enterococcus faecium BM4147. All five genes of the vanA 
gene cluster (vanR, vanS, vanH, vanX, vanY) were amplified and sequenced. No vanZ gene 
was detected. The vanA operon in P. thiaminolyticus RSA1221 was found not to be 
associated with any known mobile elements. The observed constitutive expression of 
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